Article: Novozymes Plans Takeover Of GroPep For $72M Cash.

West Coast Editor

Novozymes A/S is following up last month's buyout of a recombinant protein company from Sanofi-Aventis Group with another proposed acquisition, this time making a play for the Australian firm GroPep Ltd., which Novozymes plans to take over in a deal valued at about A$95.5 million (US$72.5 million).

Under the terms, Novozymes, of Bagsvaerd, Denmark (which owns no shares in GroPep), would pay A$2.05 in cash per share for the company, amounting to a premium of 40 percent over the price of GroPep shares the day before the proposal was disclosed, and a 33 percent premium over the past three months.

GroPep's shares (ASX:GRO) closed ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!